Clinical trials for the injectable HIV prevention drug lenacapavir have yielded significant results, with the drug proving 89% more effective than daily oral pre-exposure prophylaxis among gay, bisexual and transgender individuals, NBC News reported Sept. 13.
Read the full post on Becker's Hospital Review | Healthcare News & Analysis
